Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by kuatoliveson Jun 15, 2016 5:07pm
110 Views
Post# 24968975

RE:RE:RE:RE:QLT & Aegerion

RE:RE:RE:RE:QLT & AegerionI dunno, nothing has changed since the announcement of the merger other than they actually DID go through with the merger, DID re-apply for the Yosprala NDA, and DID relocate - if to Canada rather than Ireland. They haven't actually not done anything they stated, as opposed to a really big turd such as PHM that was nothing but a fascade that you could somehow take distressed assets, mash them together, and create a gold brick. I feel more sorry for those guys because they got suckered by the fast talkers on BNN and ended up losing tons of money they will likely never recover. As for ARLZ - again, nothing has deviated from the plan as laid in the merger - other than the stock price tanking. As far as anyone knows, we're still on track for Yosprala approval this year, and a couple hundred million in revenue in a few years.  Don't let Mr. Market get you down. Yeah, sometimes he's trying to tell you something (Enron, etc), but unless we're missing something here, nothing has changed since June 2015 other than the sp @ 2 bucks.

Yeah, we did get screwed with the merger, and if I saw Harris I'd have words for him, but its a valuable lesson in this game - you can still go broke being right; but there's nothing to say the biotech bubble couldn't have continued another year with another wave of takeovers and doubled us up again from 2 bucks.

Couple of lessons I'd learned. I'd bought PLI waaaay back at 50 cents and I think it went down to like .39 or something and I was having a heart attack because I'd lost a ton of money on paper or something. I bailed and then rebought again at a buck. Another 10% loss and I was like 'here we go again!'. I sold and then watched a rally to $3+.   Ditto for Tribute. Started buying at .75 and averaged down as it fell to .48 or something. Those are big % losses there. Maybe I'm just being sensitive to my past here, but I haven't seen a reason to sell ARLZ that wasn't rooted in negative stockholder sentiment. Not going to make that mistake again.  I'm also prepared for the eventuality there is no real pop on Yosprala approval - that we'll actually have to wait for real earnings after that - and that's the way it should be. But we'll see, I could be wrong. Have been many times.

<< Previous
Bullboard Posts
Next >>